
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Don’t miss our latest news! Sign up today for our free newsletter.
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Antiretroviral regimens that do not contain a protease inhibitor might put HIV-positive women at a greater risk of developing insulin resistance and diabetes, according to a study in the May 15 edition of the journal Clinical Infections Diseases. Earlier studies suggested a link between the conditions and antiretroviral drug--with protease inhibitors suspected as the cause of blood sugar abnormalities. But researchers in New York who studied 332 HIV-positive middle-aged women found that insulin resistance, a diabetes precursor, was reported in 26% of the women on nonprotease-based regimens, compared with 12% taking protease inhibitors. Women not on protease-based therapy also were more likely to have impaired glucose tolerance. Other prediabetes and diabetes risk factors included obesity and a family history of the disease. All HIV-positive women should be closely monitored for signs of diabetes, the researchers say, with particular attention given to those not on protease-based regimens.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Don’t miss our latest news! Sign up today for our free newsletter.
Plus: Featured Video
Latest Stories
‘Kokomo City’ Gives a Searing Look Into Lives of Black Trans Sex Workers
August 18 2023 12:40 PM